Angioplasty.Org
Most Popular Angioplasty Web Site
   
supported by Volcano Corporation
Volcano Corporation Announces Record Preliminary Fourth Quarter 2012 Revenues
Quarterly FFR Disposable Revenues Increase 45 Percent
Year-Over-Year On A Constant Currency Basis
Share This Story:
Email
Bookmark and Share


external sites:
Volcano Corporation

FFR wire
Fractional Flow Reserve disposable revenue increased 45%
January 7, 2013 -- San Diego -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that it expects total revenues for the fourth quarter of 2012 will be approximately $102.5 million, bringing expected full year 2012 revenues to approximately $381.9 million.

Medical segment revenues in the fourth quarter of 2012 increased approximately 10 percent on a reported basis and 12 percent on a constant currency basis versus the fourth quarter of 2011, driven by an increase in FFR (Fractional Flow Reserve) disposable revenues of approximately 42 percent year-over-year on a reported basis and 45 percent on a constant currency basis.

The expectations for revenues in the fourth quarter of 2012 reflect an increase of approximately 10 percent on a reported basis and 12 percent on a constant currency basis versus revenues of $92.7 million in the fourth quarter a year ago. The expected revenues for all of 2012 reflect an increase of approximately 11 percent on a reported basis and 12 percent on a constant currency basis versus revenues of $343.5 million in 2011.

"The growth of our medical disposable business, which increased approximately 11 percent on a constant currency basis in the quarter, reflects the value of our functional PCI market development strategies as healthcare providers increasingly seek to document proof of necessity and treatment outcomes," said Scott Huennekens, president and chief executive officer.

"We generated excellent growth in our FFR disposable business across all of our key geographies, driven by data that demonstrate the use of FFR results in improved patient outcomes as well as the more cost-effective delivery of therapy. These gains were offset by the continued challenges of the macroeconomic environment in the U.S. and Europe that negatively impacted PCI activity," he added.

The company said it is providing the estimated revenues for 2012 in advance of meetings with the investment community and its presentation at the 31st Annual J.P. Morgan Healthcare Conference. The company's presentation will occur at 11 a.m., Pacific Standard Time (2 p.m., Eastern Standard Time), Tuesday, January 8. A webcast of the presentation will be available through the conference website at http://jpmorgan.metameetings.com/webcasts/healthcare13/directlink?ticker=VOLC and via the company's website at www.volcanocorp.com.

The company's complete fourth quarter and full year 2012 financial results and guidance for 2013 will be provided in a press release, as well as a conference call and publicly available webcast, in late February. Details regarding the date of the earnings press release, conference call and webcast will be provided in a subsequent press release.

About Volcano
Volcano Corporation is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive. Our products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information—using sound and light as the guiding elements. Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together. For more information, visit the company's website at www.volcanocorp.com.

Full data here

Source: Volcano Corporation